Neratinib Shrank Brain Mets in Half of HER2+ Breast Cancer Patients

Video

This video examines results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients.

Rachel A. Freedman, MD, on Neratinib in HER2-Positive Breast Cancer Patients With CNS Involvement
Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Rachel A. Freedman, MD, MPH, of the Dana-Farber Cancer Institute, discusses results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients.

      Freedman presented the results of the study (abstract 1005) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

      Related Content